SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be available live and for 90 ...

Core Insights - Cytokinetics, Inc. is a biopharmaceutical company focused on developing treatments for cardiovascular diseases, leveraging over 25 years of expertise in muscle biology [1] - The company is set to release its fourth-quarter earnings on February 24, 2026, with investors closely monitoring the anticipated financial results [1] Financial Performance Expectations - Wall Street estimates that Cytokinetics will report an earnings per share (EPS) of -$1.48, with revenue expected to be around $8.02 million, indicating a quarterly loss [2] - The anticipated decline in earnings and revenue compared to the previous year suggests that the company may not achieve an earnings beat in its upcoming report [2] Financial Metrics Analysis - Cytokinetics has a negative price-to-earnings (P/E) ratio of -10.86, indicating it is not currently profitable [3] - The price-to-sales ratio is approximately 95.39, suggesting that investors are paying a high price for each dollar of sales [3] - The enterprise value to sales ratio is around 106.53, reflecting a premium valuation relative to its sales [3] Liquidity and Cash Flow - The company maintains a strong current ratio of 6.88, indicating its ability to cover short-term liabilities with short-term assets [4] - The enterprise value to operating cash flow ratio of -21.46 highlights difficulties in generating positive cash flow from operations [4] - The debt-to-equity ratio of -2.30 suggests more liabilities than equity, which could be a concern for investors [4] Upcoming Earnings Call - The earnings call scheduled for 4:30 PM Eastern Time on February 24 will be crucial for insights into the sustainability of stock price changes and future earnings expectations [5] - Investors can access the live webcast through the company's website, with an archived replay available for six months [5]

Baker Bros. Advisors reported a buy of 2,005,813 Kymera Therapeutics (NASDAQ:KYMR) shares in its February 17, 2026, SEC filing, an estimated $135.45 million trade based on quarterly average pricing. What happened According to a February 17, 2026 SEC filing, Baker Bros. increased its holding in Kymera Therapeutics (NASDAQ:KYMR) by 2,005,813 shares. The estimated trade value was $135.45 million, based on the average closing price during the fourth quarter of 2025. The fund’s quarter-end position value in K ...

On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing. What happened According to a recent SEC filing, Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during the fourth quarter of 2025. The estimated value of the transaction is $81.38 million, calculated using the period's average closing price. The post-trade stake stood at 1,126,488 ...

On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 2,608,696 shares of Kodiak Sciences (NASDAQ:KOD), an estimated $53.42 million trade based on quarterly average pricing. What happened According to its SEC filing dated February 17, 2026, Baker Bros. Advisors LP increased its position in Kodiak Sciences (NASDAQ:KOD) by 2,608,696 shares during the fourth quarter of 2025. The estimated transaction value was $53.42 million, calculated using the average unadjusted closing price for the quarter. ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential On February 20, Barclays began coverage of Bristol-Myers Squibb Company (NYSE:BMY) with an Overweight rating and a $75 price target. The analyst acknowledged that the company is approaching a difficult period, pointing to a “patent cliff” as exclusivity for key drugs like Eliquis and Opdivo moves closer to ex ...

Core Insights - Axsome Therapeutics reported an earnings per share (EPS) of -$0.56 for February 23, 2026, which was better than the expected -$0.70, indicating better-than-anticipated performance [1] - The company achieved a revenue of approximately $196 million, surpassing the estimated $193.3 million, suggesting successful sales growth [2] Financial Metrics - The price-to-sales ratio stands at 16.50, reflecting investor confidence in the company's future growth potential [2] - Axsome has a negative P/E ratio of -40.04 and an earnings yield of -2.50%, indicating a lack of profitability [3] - The current ratio of 1.57 suggests a reasonable level of short-term liquidity to cover current liabilities [3] Valuation and Debt - The enterprise value to sales ratio is 16.31, indicating that the company's valuation is closely tied to its revenue [4] - The enterprise value to operating cash flow ratio is significantly negative at -90.69, highlighting challenges in generating positive cash flow from operations [4] - The debt-to-equity ratio of 2.96 indicates a higher level of debt compared to equity, which could pose risks if the company cannot generate sufficient cash flow to service its debt [4]

Core Viewpoint - Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science, developing innovative therapies for serious diseases, with two approved C3-targeting medicines [1] Financial Performance - Apellis is set to release its quarterly earnings on February 24, 2026, with Wall Street estimating an earnings per share (EPS) of -$0.39 and analysts predicting a slightly larger loss of -$0.41 per share [2][6] - Revenue projections are estimated at $199.4 million by Wall Street and $199 million by analysts [2] - The current stock price is $22.28, reflecting a 2.3% decrease, with a market capitalization of $2.82 billion and a price-to-earnings (P/E) ratio of 71.87 [3][6] Stock Performance - Over the past year, APLS stock has fluctuated between a low of $16.10 and a high of $30.48 [3] - The fifty-day simple moving average is $23.31, while the two-hundred-day simple moving average is $23.87 [3] Financial Ratios - The company maintains a quick ratio of 3.10 and a current ratio of 3.54, indicating strong liquidity [4][6] - The debt-to-equity ratio is 0.90, showing moderate financial leverage [4][6] - The price-to-sales ratio is 2.77, and the enterprise value to sales ratio is also 2.77, reflecting its market value compared to sales [4] Market Expectations - The upcoming earnings report is crucial for APLS as it could influence the stock's near-term price movement, with potential upward trends if results exceed expectations [5] - The sustainability of any immediate price changes will depend on management's discussion during the earnings call [5]

ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Monday following the company’s announcement of significant revenue growth. • ImmunityBio stock is challenging resistance. Why are IBRX shares at highs?The stock has jumped around 55% over the last month, thanks to investor interest after preliminary earnings and several strategic partnerships.The company’s lead drug, Anktiva, is approved in the U.S. and several international markets for BCG-unresponsive NMIBC with carcinoma in situ.700% Sales JumpImmunityBio r ...

LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will ...